Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Evidence for oestrogen sensitivity in perinatal depression: pharmacological sex hormone manipulation study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diagnostic value of oligoclonal bands in children: A Nationwide Population-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Illegal cannabis use is common among Danes with multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Smoking has been associated with increased multiple sclerosis (MS) risk, disease worsening, and progression in MS patients. Furthermore, interactions between smoking and human leukocyte antigen (HLA) genes have been shown for MS risk. Recently, we found that smoking was associated with an increased relapse rate in interferon-beta-treated relapsing-remitting multiple sclerosis (RRMS) patients.

OBJECTIVES: We examined the association between smoking and relapses in natalizumab-treated RRMS patients. Second, we investigated if an interaction between smoking and HLA-DRB1*15:01 or HLA-A*02:01 affected the number of relapses during treatment.

METHODS: In this observational cohort study, 355 natalizumab-treated RRMS patients were assessed. Prespecified criteria excluded 62 patients. Clinical data from the starting of treatment to the two-year follow-up visit were collected. Smoking status was obtained by a questionnaire survey. TaqMan allelic discrimination was used for genotyping of tag single-nucleotide polymorphisms (SNPs) for HLA-DRB1*15:01 and HLA-A*02:01. Negative binomial regression analysis was used to analyze the association between relapse rate and smoking intensity and HLA.

RESULTS: One pack of cigarettes (20 cigarettes) per day during natalizumab treatment increased the relapse rate during treatment with 38% (incidence rate ratio (IRR) = 1.38, 95% confidence interval (CI): 1.08-1.77, p = 0.01). No association or interaction was found between smoking and HLA-DRB1*15:01 or HLA-A*02:01, respectively.

CONCLUSION: Smoking intensity was significantly associated with the number of relapses during natalizumab treatment.

Original languageEnglish
JournalMultiple sclerosis (Houndmills, Basingstoke, England)
Volume25
Issue number9
Pages (from-to)1298-1305
Number of pages8
ISSN1352-4585
DOIs
Publication statusPublished - Aug 2019

ID: 58251333